ATE402739T1 - Behandlung von entzündungen - Google Patents

Behandlung von entzündungen

Info

Publication number
ATE402739T1
ATE402739T1 AT05813139T AT05813139T ATE402739T1 AT E402739 T1 ATE402739 T1 AT E402739T1 AT 05813139 T AT05813139 T AT 05813139T AT 05813139 T AT05813139 T AT 05813139T AT E402739 T1 ATE402739 T1 AT E402739T1
Authority
AT
Austria
Prior art keywords
a3ar
inflammatory state
subject
level
wbc
Prior art date
Application number
AT05813139T
Other languages
English (en)
Inventor
Pnina Fishman
Sara Bar-Yehuda
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE402739(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Application granted granted Critical
Publication of ATE402739T1 publication Critical patent/ATE402739T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rehabilitation Therapy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT05813139T 2004-12-02 2005-11-30 Behandlung von entzündungen ATE402739T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63219804P 2004-12-02 2004-12-02
US65771805P 2005-03-03 2005-03-03

Publications (1)

Publication Number Publication Date
ATE402739T1 true ATE402739T1 (de) 2008-08-15

Family

ID=35708899

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05812529T ATE434762T1 (de) 2004-12-02 2005-11-30 Biologischer marker für entzündung
AT05813139T ATE402739T1 (de) 2004-12-02 2005-11-30 Behandlung von entzündungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT05812529T ATE434762T1 (de) 2004-12-02 2005-11-30 Biologischer marker für entzündung

Country Status (13)

Country Link
US (3) US20080056992A1 (de)
EP (2) EP1817589B1 (de)
JP (2) JP4842964B2 (de)
KR (2) KR20070100261A (de)
AT (2) ATE434762T1 (de)
AU (2) AU2005310873B2 (de)
BR (2) BRPI0518777A2 (de)
CA (2) CA2586773C (de)
DE (2) DE602005015135D1 (de)
DK (1) DK1817079T3 (de)
ES (2) ES2327435T3 (de)
MX (2) MX2007006500A (de)
WO (2) WO2006059327A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007043054A1 (en) * 2005-10-12 2007-04-19 Can-Fite Biopharma Ltd. Treatment and monitoring disease state of liver cancer
US20080300213A1 (en) 2005-11-30 2008-12-04 Pnina Fishman Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment
US20080183101A1 (en) * 2006-08-17 2008-07-31 Jonathan Richard Stonehouse Salivary analysis
WO2008023362A2 (en) * 2006-08-21 2008-02-28 Can-Fite Biopharma Ltd. Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
WO2008056361A1 (en) * 2006-11-09 2008-05-15 Can-Fite Biopharma Ltd. A biological marker for psoriasis
US9102698B2 (en) 2007-03-14 2015-08-11 Can-Fite Biopharma Ltd. Process for the synthesis of IB-MECA
IL200753A (en) * 2009-09-06 2015-06-30 Can Fite Biopharma Ltd Pharmaceutical preparation containing ib – meca for the treatment of psoriasis
US20130045943A1 (en) * 2010-03-03 2013-02-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of A3ar agonists for the treatment of uveitis
EP2583972B1 (de) * 2010-06-18 2018-04-18 Hayashibara Co., Ltd. Therapeutikum für entzündungskrankheiten mit adenosin-n1-oxid als wirkstoff
KR102095284B1 (ko) 2017-05-11 2020-04-01 (주)케어젠 메토트렉세이트와 펩타이드의 결합체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181351A4 (de) 1984-05-09 1989-06-21 Univ Australian Verfahren zur modulierung der immunologischen antwort.
AU5182500A (en) 1996-08-01 2000-10-26 Kennedy Institute Of Rheumatology, The Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease
ATE247974T1 (de) 1996-12-06 2003-09-15 Amgen Inc Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
US20020179549A1 (en) * 2001-06-04 2002-12-05 Chris Felcman System and method for mounting a keyboard and display assembly in a 1U rack space
JP2004135657A (ja) * 2002-08-21 2004-05-13 Kyowa Hakko Kogyo Co Ltd ヒトａ３アデノシン受容体を発現するトランスジェニック非ヒト哺乳動物
WO2004036215A2 (en) * 2002-10-21 2004-04-29 Can-Fite Biopharma Ltd. Diagnostic markers for therapeutic treatment
US20040229246A1 (en) * 2002-10-21 2004-11-18 Can-Fite Biopharam Ltd. Diagnostic markers for therapeutic treatment
ATE371191T1 (de) * 2002-10-22 2007-09-15 Can Fite Biopharma Ltd Die verwendung von dem a3 adenosin rezeptor als marker eines krankheitszustandes
WO2004045627A1 (en) * 2002-11-19 2004-06-03 Can-Fite Biopharma Ltd. A3ar agonists for the treatment of inflammatory arthritis
WO2004086034A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3)
UY28391A1 (es) 2003-06-25 2004-12-31 Elan Pharm Inc Metodos y composiciones para tratar artritis reumatoide
EP1699459B1 (de) 2003-12-29 2007-06-06 Can-Fite Biopharma Ltd. Verfahren zur behandlung von multipler sklerose

Also Published As

Publication number Publication date
AU2005310874A1 (en) 2006-06-08
CA2586774A1 (en) 2006-06-08
AU2005310873B2 (en) 2008-11-27
JP2008521883A (ja) 2008-06-26
DE602005008639D1 (de) 2008-09-11
US20080056992A1 (en) 2008-03-06
JP2008522182A (ja) 2008-06-26
CA2586773A1 (en) 2006-06-08
WO2006059328A1 (en) 2006-06-08
ES2327435T3 (es) 2009-10-29
EP1817589B1 (de) 2009-06-24
DE602005015135D1 (de) 2009-08-06
MX2007006500A (es) 2007-07-13
EP1817589A1 (de) 2007-08-15
MX2007006501A (es) 2007-07-13
EP1817079A1 (de) 2007-08-15
WO2006059327A1 (en) 2006-06-08
AU2005310874B2 (en) 2008-11-27
JP4842964B2 (ja) 2011-12-21
BRPI0518777A2 (pt) 2008-12-09
CA2586773C (en) 2018-03-27
EP1817079B1 (de) 2008-07-30
AU2005310873A1 (en) 2006-06-08
US20100256084A1 (en) 2010-10-07
KR20070090222A (ko) 2007-09-05
DK1817079T3 (da) 2008-11-17
KR20070100261A (ko) 2007-10-10
US20130345163A1 (en) 2013-12-26
BRPI0518795A2 (pt) 2008-12-09
US8541182B2 (en) 2013-09-24
ATE434762T1 (de) 2009-07-15
ES2309817T3 (es) 2008-12-16

Similar Documents

Publication Publication Date Title
Qureshi et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients
Błogowski et al. Clinical analysis of perioperative complement activity during ischemia/reperfusion injury following renal transplantation
WO2007123976A3 (en) Antibody profiling for determination of patient responsiveness
WO2005103281A3 (en) Platelet biomarkers for the detection of disease
ATE402739T1 (de) Behandlung von entzündungen
WO2009025847A3 (en) Methods for diagnosis, prognosis and methods of treatment
DE602004001227D1 (de) Nukleinsäure-biosensor
WO2004097052A3 (en) Methods for prognosis and treatment of solid tumors
EA200500218A1 (ru) ЛЕЧЕНИЕ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ С ПРИМЕНЕНИЕМ ИНТЕРФЕРОНА-β
EP2300599A4 (de) Steigerung der wirksamkeit einer zelltherapie, einschliesslich behandlung mit alpha-1-3-fucosyltransferase
NO20072296L (no) Fremgangsmater og systemer for prognose og behandling av faste tumorer
ATE556717T1 (de) Neutralisierung monoklonaler antikörper gegen mit schwerem akutem respirationssyndrom assoziiertem coronavirus
Bongers et al. Impact of acute versus repetitive moderate intensity endurance exercise on kidney injury markers
JP2017522555A5 (de)
Novaes et al. Parasite control and skeletal myositis in Trypanosoma cruzi-infected and exercised rats
MX2009001070A (es) Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma.
DK2068938T3 (da) Optimering af behandlingen af Philadelphia-positiv leukæmi med ABL-tyrosinkinaseinhibitor imatinib
EA201500526A1 (ru) Композиции и методы лечения воспалительных заболеваний инфекционного и неинфекционного происхождения
BRPI0407213A (pt) Método de emprego da elevação de marinobufagenina na determinação da presença de pré-eclampsia e aparelhos relacionados
WO2007044622A8 (en) Use of mif and mif pathway agonists
Reudelhuber Where hypertension happens
Gangemi et al. Effect of therapeutic plasma exchange on plasma levels of oxidative biomarkers in a patient with thrombotic thrombocytopenic purpura
BRPI0418022A (pt) biomarcadores para sensibilidade de doenças proliferativas a inibidores de mtor
EA201001340A1 (ru) Улучшенный аналитический способ для определения латентного гепатита с, его применения и соответствующий диагностический набор
Diskin Erythropoietin levels and androgens use: what is their relationship in the correction of anemia?

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1817079

Country of ref document: EP

REN Ceased due to non-payment of the annual fee